Novartis Admits to ‘Mistake’ After Partial Clinical Hold Placed on Zolgensma Trial

Novartis on Wednesday said that the US Food and Drug Administration (FDA) placed a partial hold on intrathecal clinical trials of its gene therapy Zolgensma (onasemnogene abeparvovec-xioi) for spinal muscular atrophy (SMA) patients based on findings in a small preclinical animal study.